Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant-Reference-Cited by-同舟云学术

Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant

Published:2021-04-21 Issue:5 Volume:5 Page:e561
ISSN:2572-9241
Container-title:HemaSphere
language:en
Short-container-title:

Author:

Holthof Lisa C.,Stikvoort Arwen,van der Horst Hilma J.,Gelderloos Anne T.,Poels Renée,Li Fengzhi,Groen Richard W. J.,Zweegman Sonja,van de Donk Niels W. C. J.,O’Dwyer Michael,Mutis Tuna

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hematology

Reference28 articles.

1. Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance.;de Haart;Clin Cancer Res,2013

2. Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance.;de Haart;Haematologica,2016

3. A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity.;Ling;PLoS One,2012

4. Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma.;Holthof;Haematologica,2020

5. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor.;van der Sloot;Proc Natl Acad Sci U S A,2006

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TGF-β: an active participant in the immune and metabolic microenvironment of multiple myeloma;Annals of Hematology;2024-06-20

2. The role of MSCs and CAR-MSCs in cellular immunotherapy;Cell Communication and Signaling;2023-08-01

3. Early TRAIL-engagement elicits potent multimodal targeting of melanoma by CD34+ progenitor cell-derived NK cells;iScience;2023-07

4. Overcoming the challenges in translational development of natural killer cell therapeutics: An opinion paper;Frontiers in Oncology;2022-12-02

5. Overcoming tumor resistance mechanisms in CAR-NK cell therapy;Frontiers in Immunology;2022-08-03